Abstract
Clinical outcomes resulting from SARS-CoV-2 infection vary widely, ranging from asymptomatic cases to the development of mild to severe respiratory illness, and in some instances, chronic lingering disease and mortality. The underlying biological mechanisms driving this wide spectrum of pathogenicity among certain individuals and demographics remain elusive. Autoantibodies have emerged as potential contributors to the severity of COVID-19. Although preliminary reports have suggested the induction of antibodies targeting Angiotensin-Converting Enzyme II (ACE2) post-infection, this assertion lacks confirmation in large-scale studies. In this study, our objective is to comprehensively characterize and quantify the prevalence and expression levels of autoantibodies directed against ACE2 in a sizable cohort (n = 434). Our findings reveal that ACE2-reactive IgM antibodies are the most prevalent, with an overall seroprevalence of 18.8%, followed by IgG at 10.3% and IgA at 6.3%. Longitudinal analysis of individuals with multiple blood draws showed stable ACE2 IgG and IgA levels over time. Upon stratifying individuals based on molecular testing for SARS-CoV-2 or serological evidence of past infection, no significant differences were observed between groups. Functional assessment of ACE2 autoantibodies demonstrated that they are non-neutralizing and failed to inhibit spike-ACE2 interaction or affect the enzymatic activity of ACE2. Our results highlight that ACE2 autoantibodies are prevalent in the general population and were not induced by SARS-CoV-2 infection in our cohort. Notably, we found no substantiated evidence supporting a direct role for ACE2 autoantibodies in SARS-CoV-2 pathogenesis.
Lay Summary This study examined the natural presence and function of autoantibodies targeting ACE2, the receptor for SARS-CoV-2, to determine if they influence COVID-19 severity. Using a cohort of over 400 individuals, including those with prior SARS-CoV-2 infection, we assessed the prevalence of ACE2-reactive IgM, IgG, and IgA antibodies in the general population. ACE2-reactive IgM antibodies were most common, found in approximately 18.8% of participants, followed by IgG at 10.3% and IgA at 6.3%.
Longitudinal analysis showed stable levels of IgG and IgA, with fluctuations in IgM over time. Importantly, no significant difference in ACE2 antibody levels was observed between individuals with or without SARS-CoV-2 infection, suggesting these autoantibodies were not induced by COVID-19. Functional tests showed that these ACE2 autoantibodies did not inhibit the virus’s spike-ACE2 interaction or alter ACE2’s enzymatic activity, indicating they are non-neutralizing.
We conclude that ACE2 autoantibodies are commonly present in the general population, independent of SARS-CoV-2 exposure, and are unlikely to play a role in COVID-19 severity. Further research is required to explore any potential physiological or pathological significance of ACE2 autoantibodies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Canadian Institute of Health Research (CIHR) grant (VR2-172722) and from a supplement by the COVID-19 Immunity Task Force (CITF) to M-A.L.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was granted by The Ottawa Health Science Network Research Ethics Board (Certificates: H-09-20-6135 and H-07-20-6009). Informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
